1325P Checkpoint inhibitor monotherapy in potentially study-eligible or non-study-eligible NSCLC patients in the German CRISP registry real-world cohort (AIO-TRK-0315)

Abstract

therefore a feasible tool is urgently needed to predict the patients who might benefit from ICIs in clinical practice. Methods:We enrolled 76 patients with advanced NSCLC and treated them with ICIs in three independent cohorts. Using transcriptome data analysis of a training set (n¼35), we constructed a predictive signature consisting of immune-related gene pairs (IRGPs). The predictive signature was first validated in the testing set (n¼20) and then validated in an independent cohort containing 19 patients recruited from the Cancer Hospital/Institute, Chinese Academy of Medical Sciences (CICAMS).Results: Based on a gene expression profile from the GSE93157 database, we proposed the IRGP index (IRGPI): four IRGPs were significantly associated with progression-free survival (PFS) of patients with NSCLC treated with ICIs. We then validated the IRGPI using a test set and its prognostic performance was further verified at various protein levels in an additional independent set. Stratification and multivariate Cox regression analyses revealed that IRGPI was an independent prognostic predictor. Notably, IRGPI exhibited more powerful predictive performance than PD-L1. Further analysis revealed that the IRGPI-low and PD-L1-high subgroups showed the best response to anti-PD-1 immunotherapy.Conclusions: Our study highlights the potential predictive value of IRGPI for responses of ICIs in advanced NSCLC. This signature may be a powerful prognostic tool and help further optimise the use of ICIs.

Ambulatory Routine Care in Oncology in Germany: Real-World Survival Data

“…Indeed these subgroups differed significantly regarding median OS, with “potentially trial-eligible” patients showing a significantly longer median OS of 26.2 months, which was then comparable to the OS reported in RCTs [ 8 ]. We also evaluated the impact of trial eligibility on treatment, survival, and patient-reported outcome of patients with advanced NSCLC treated with pembrolizumab monotherapy in first line in routine care, seeing that almost 50% of the patients would not have met eligibility criteria for RCTs [ 62 ]. These findings are of substantial relevance for physicians discussing outcomes with their patients.…”

Impact of pembrolizumab treatment duration on overall survival and prognostic factors in advanced non-small cell lung cancer: a nationwide retrospective cohort study

“…A recent study showed that trial-ineligible metastatic NSCLC patients treated with pembrolizumab monotherapy had significantly worse outcomes than trial-eligible patients. 12 Another difference between clinical trials and everyday practice is treatment duration. In KEYNOTE-189, the maximal duration of pembrolizumab was 2 years (35 cycles), whereas the EMA authorized continuation of pembrolizumab after this date.…”